Johnson & Johnson (JNJ) Company Profile

Johnson & Johnson (JNJ) is a diversified healthcare conglomerate operating in three main segments: Pharmaceuticals (its largest and most profitable), MedTech (medical devices), and Consumer Health (now spun off as Kenvue). It sells prescription drugs, surgical tools, and well-known consumer brands like Tylenol. Its customers range from hospitals and governments to individual consumers, creating a diversified revenue base. Using the GoodMoat framework, JNJ exhibits several durable advantages. It scores strongly on Brand & Culture (criterion 6), with essential trust in its consumer and medical products, and Regulatory Barriers (5), as its drug patents and approval processes are significant hurdles for competitors. Its massive scale and vertical integration in research and manufacturing (criteria 4 & 8) provide cost and efficiency advantages. However, risks to monitor include Regulatory/Geopolitical Risk (Red Flag 7), as drug pricing and patent cliffs are constant pressures, and potential Growth Deceleration (Red Flag 13), with a current revenue growth of 9.1% YoY. While its ROE of 32.9% and profit margin of 28.5% indicate high quality, the valuation is a key consideration. The GoodMoat target price of $210.09 suggests the current price of $239.93 may be unfavourable, indicating a slim or negative margin of safety for a value investor seeking a discount to intrinsic value.